Michael D Taylor

Michael D Taylor, M.D., PhD.

Picture

Michael D Taylor, M.D., PhD.

Professor

Email

michael.taylor@bcm.edu

Positions

Professor: Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine
Houston, Texas United States

Director: Pediatric Brain Tumor Research Program
Texas Children’s Hospital
Houston, Texas United States

Member: Baylor College of Medicine
Dan L Duncan Comprehensive Cancer Center

The Cyvia and Melvyn Wolff Chair of Pediatric Neuro-Oncology: Texas Children's Cancer and Hematology Center
Section of Hematology-Oncology
Texas Childeren's Hospital

Scholar: Cancer Prevention and Research Institute of Texas (CPRIT)
Houston, Texas United States

Addresses

Feigin Center (Office)
: TX CHILDS FEIGIN CTR (TXFC)
1102 Bates Avenue
Houston, TX 77030
United States
Phone: (832) 824-4032
michael.taylor@bcm.edu

Education

MD from University of Western Ontario: 06/1994 - London, Ontario Canada

PhD from University of Toronto: 06/2002 - Toronto, Ontario Canada

Residency at University of Toronto: 06/2003 - Toronto, Ontario Canada; Neurosurgery

Postdoctoral Fellowship at St Jude Children’s Research Hospital: 06/2004 - Memphis, Tennessee United States; Cancer Genomics

Postdoctoral Fellowship at University of Toronto: 07/2005 - Toronto, Ontario Canada; Functional Genomics

Professional Interests

Brain Tumors

Professional Statement

I am a Pediatric Neurosurgeon and Scientist at the Baylor College of Medicine affiliated Texas Children’s Hospital. I am also Director of the Texas Children’s Pediatric Brain Tumor Research Program and the Cyvia and Melvyn Wolff Chair of Pediatric Neuro-Oncology. My laboratory and the Program are located in the Feigin Center in Houston, Texas. My research centers on the molecular genetics of medulloblastoma and ependymoma, two of the most common malignant pediatric brain tumors.
My team have published over 400 peer-reviewed publications, many in high-impact journals such as Nature, Science, Cell, Cancer Cell, and Lancet Oncology. These publications have been cited over 70,000 times and the findings adopted to improve clinical practice for children with brain cancer.
My group demonstrated that medulloblastoma is comprised of at least four distinct diseases (Journal Clinical Oncology, 2011; Cancer Cell, 2017; Nature, 2017) and that there is clinically significant heterogeneity in metastatic medulloblastomas (Nature, 2012; Nature, 2016; Nature Genetics, 2017). My team recently showed that these cerebellar tumors are a disorder of early brain development, a finding which provides a proximate explanation for the peak incidence of cerebellar tumors in early childhood (Nature, 2019; Nature, 2022; Cell, 2024).
People often note my quick wit and strong collaboration skills. Nearly every member of the lab has at some point been “Taylorized” — if you’re wondering what that is then please email me for current opportunities so you can come and join the adventure!